Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.
Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.
复制标题
基于 HCV 基因型 1b 感染患者 IL28B 基因附近遗传多态性的聚乙二醇干扰素和利巴韦林联合治疗期间早期病毒动态的预测价值。
DOI：
10.1002/jmv.22272
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Matsuda F.
中科院分区：
文献类型：
--
作者：
Toyoda H;Kumada T;Tada T;Hayashi K;Honda T;Katano Y;Goto H;Kawaguchi T;Murakami Y;Matsuda F.
进行了一项研究，以确定早期病毒动力学是否保留对聚乙二醇干扰素 (PEG-IFN) 和利巴韦林联合治疗结果的预测，该结果基于 IL28B 基因附近的不同遗传多态性，IL28B 基因是对该治疗反应的最强基线预测因子。根据IL28B基因（rs8099917）附近的遗传多态性对总共272名感染丙型肝炎病毒（HCV）基因型1b的患者进行分组。根据这些基因型评估开始治疗后 4 周和 12 周时 HCV RNA 水平降低预测持续病毒学应答的能力。在rs8099917 TT基因型（与良好反应相关）的患者中，开始治疗后4周血清HCV RNA水平降低≥3 log10的患者持续病毒学缓解率较高（P<0.0001）。相比之下，在 TG/GG 基因型（与不良反应相关）的患者中，根据 4 周时 HCV RNA 水平的降低，这一比率没有差异。开始治疗后 4 周的早期病毒动态对于 rs8099917 TT 基因型患者保留了其持续病毒学应答的预测价值，但对于 TG/GG 基因型患者则不然。尽管 TG/GG 基因型不利，但根据治疗期间的早期病毒动态无法识别哪些患者可能实现持续病毒学应答。相比之下，无论 IL28B 多态性如何，12 周时缺乏早期病毒学应答仍对持续病毒学应答失败具有很强的预测价值，这仍然是停止治疗的有用因素。 J. Med。病毒。 84:61–70，2011 年。© 2011 Wiley periodicals, Inc.
A study was carried out to determine whether early viral dynamics retain prediction of the outcome of peginterferon (PEG‐IFN) and ribavirin combination therapy based on different genetic polymorphisms near theIL28Bgene, the strongest baseline predictor of response to this therapy. A total of 272 patients infected with hepatitis C virus (HCV) genotype 1b were grouped according to genetic polymorphisms near theIL28Bgene (rs8099917). The ability of reduced HCV RNA levels at 4 and 12 weeks after starting therapy to predict a sustained virologic response was evaluated based on these genotypes. Among patients with the TT genotype for rs8099917 (associated with a favorable response), the rates of sustained virologic response were higher in patients with a ≥3 log10reduction in serum HCV RNA levels at 4 weeks after starting therapy (P< 0.0001). In contrast, among patients with the TG/GG genotype (associated with an unfavorable response), there were no differences in this rate based on the reduction in HCV RNA levels at 4 weeks. Early viral dynamics at 4 weeks after starting therapy retains its predictive value for sustained virologic response in patients with the TT genotype for rs8099917, but not in patients with the TG/GG genotype. Patients who are likely to achieve sustained virologic response despite unfavorable TG/GG genotype cannot be identified based on early viral dynamics during therapy. In contrast, lack of early virologic response at 12 weeks retains a strong predictive value for the failure of sustained virologic response regardless ofIL28Bpolymorphisms, which remains useful as a factor to stop therapy. J. Med. Virol. 84:61–70, 2011. © 2011 Wiley Periodicals, Inc.